Snowball logo
logo
EFTR

Effector Therapeutics Inc

EFTR • NASDAQ
$0.0008$0.00  (0%)
Estimate
EPS
-12.78
Beta
2.737
About the company
Ticker
EFTR
ISIN
US28202V1089
Country
United States of America
Sector (GICS)
Healthcare
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Frequently asked questions

What sector does Effector Therapeutics Inc (EFTR) operate in?

Effector Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Effector Therapeutics Inc (EFTR) current stock price?

As of the latest data, Effector Therapeutics Inc stock price is $0.00, with a previous close of $0.00.

What is Effector Therapeutics Inc (EFTR) current market capitalization?

Effector Therapeutics Inc market cap is approximately 3.76 thousand.

What is Effector Therapeutics Inc (EFTR) Earnings Per Share (EPS)?

The trailing EPS is -$12.78.

Does Effector Therapeutics Inc (EFTR) pay dividends?

No. Effector Therapeutics Inc does not pay a dividend.

What is Effector Therapeutics Inc (EFTR) beta (volatility) score?

Effector Therapeutics Inc has a beta of 2.737, indicating very high volatility compared to the market.